OnKure Therapeutics, Inc. Cash Flow-to-Debt Ratio
OnKure Therapeutics, Inc. cash flow-to-debt ratio. OnKure Therapeutics, Inc. (OKUR) has a Cash Flow-to-Debt Ratio of -1.43x as of June 2026, meaning its operating cash flow of $-10.35 Million could theoretically repay -1% of its total liabilities ($7.25 Million) in one year. Check OnKure Therapeutics, Inc. (OKUR) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of OnKure Therapeutics, Inc. (2020–2025)
Cash flow-to-debt ratio of OnKure Therapeutics, Inc. from 2020 to 2025. Historical debt coverage capacity for OnKure Therapeutics, Inc. across 6 annual periods. Check OKUR cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
OnKure Therapeutics, Inc. Cash Flow-to-Debt Ratio by Year (2020–2025)
OnKure Therapeutics, Inc. cash flow-to-debt ratio by year from 2020 to 2025. Year-by-year debt coverage analysis for OnKure Therapeutics, Inc.. For the full cash flow conversion analysis, see OKUR cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -8.74x | $-51.83 Million | $5.93 Million | ▼ -89.3% |
| 2024 | -4.61x | $-51.12 Million | $11.08 Million | ▼ -1737.4% |
| 2023 | -0.25x | $-34.55 Million | $137.58 Million | ▲ +34.4% |
| 2022 | -0.38x | $-26.95 Million | $70.42 Million | ▲ +93.1% |
| 2021 | -5.58x | $-37.98 Million | $6.81 Million | ▼ -2827.6% |
| 2020 | -0.19x | $-18.54 Million | $97.34 Million | — |